1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Acadia's Nuplazid Could Have The Alzheimer's R&D Curse

 
• By Lucie Ellis-Taitt

Acadia's Nuplazid (pimavanserin) has met its primary endpoint in a Phase II study in patients with Alzheimer’s disease psychosis – but a secondary endpoint miss in the same study has triggered alarm bells for future development of the product in Alzheimer's, a historically risky scene, marred by many Phase III failures.

Acadia Pharmaceuticals Inc. has reported mixed Phase II results for its experimental Alzheimer's drug, pimavanserin, at a time when the diseases space is being watched with great interest following the recent late-stage failure of Eli Lilly & Co.'s solanezumab.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas